Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 5/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31196828 | 1.00 | JAK1 (0.54) | JAK1MEN1KMT2ANAMPTPARP1 | |
| SCHEMBL20754073 | 0.88 | JAK1 (0.53) | JAK1MEN1KMT2ANAMPTPARP1 | |
| SCHEMBL20753937 | 0.85 | JAK1 (0.51) | JAK1MEN1KMT2ANAMPTJAK2 | |
| SCHEMBL20753995 | 0.83 | JAK1 (0.51) | JAK1MEN1KMT2ANAMPTPARP1 | |
| SCHEMBL20753972 | 0.83 | JAK1 (0.53) | JAK1MEN1KMT2AJAK2 | |
| SCHEMBL20744346 | 0.81 | JAK1 (0.55) | JAK1MEN1KMT2ANAMPTJAK2 | |
| SCHEMBL20753889 | 0.80 | JAK1 (0.54) | JAK1MEN1KMT2ANAMPTPARP1 | |
| SCHEMBL20753941 | 0.80 | JAK1 (0.57) | JAK1JAK2 | |
| SCHEMBL22328952 | 0.78 | JAK1 (0.52) | JAK1MEN1KMT2APARP1CNR1 | |
| SCHEMBL20753877 | 0.78 | JAK1 (0.52) | JAK1MEN1KMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | disclosed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| EP-3668853-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-111225910-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | JAK1 2904/4885MEN1 2095/4885KMT2A 4473/4885 |
| US-20200253967-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | JAK1 2904/4885MEN1 2095/4885KMT2A 4473/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | JAK1 2582/4885MEN1 604/4885KMT2A 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.